Clinical Trial Update: TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TMV vaccine therapy alone and with pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Nasopharyngeal Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer
• Sinonasal Cancer
• Squamous Cell Carcinoma of Unknown Primary

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TMV vaccine

Snippet

Sponsor: Emory University | Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING